Its lead clinical candidate, GTB-3650, is in a Phase 1 dose-escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, while GTB-5550 targets B7-H3–expressing solid tumors and has reached the IND submission stage. However, in November 2025, the company received a Nasdaq notice that its common stock had closed below $1 per share for 30 consecutive business days, indicating non-compliance with the minimum bid price requirement for continued listing.
Cyborg Score Rationale
GT Biopharma is a pre-revenue clinical-stage biotech with early-phase programs and limited financial resources. The company faces near-term delisting risk from Nasdaq due to low stock price and limited cash runway, which creates significant execution and financing headwinds.
Top Insights
Clinical-stage biotech with no approved products; viability entirely dependent on clinical trial outcomes
Nasdaq delisting risk as of November 2025 due to stock price falling below $1 minimum bid requirement for 30+ consecutive days
Pipeline includes GTB-7550 for CD19-positive lymphoid malignancies and autoimmune diseases, expanding beyond oncology
Formerly OXIS International; rebranded and repositioned toward NK cell-based immunotherapy
Named Competitors
CAR-NK Cell Therapies — Off-the-shelf engineered NK cell platform
CAR-T Cell Therapies — T-cell mediated immunotherapy for hematologic malignancies
Immuno-Oncology Immunotherapies — Keytruda and broader immuno-oncology pipeline
Recent Developments
(April 2026) Entered into an Investigator Initiated Clinical Trial
(Q2 2026) First patient dosed in Phase 1 trial evaluating GTB-5550 for B7-H3-targeted NK cell therapy
(Q1 2026) Announced implementation of artificial intelligence-based technologies across drug discovery
Open the full interactive GT Biopharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.